Health CarePharmaceuticals and Biotechnology
  • Price (USD)330.01
  • Today's Change-4.37 / -1.31%
  • Shares traded3.74m
  • 1 Year change+43.26%
  • Beta0.3609
Data delayed at least 15 minutes, as of Sep 29 2022 21:10 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Eli Lilly and Company is engaged in a drug manufacturing business. The Company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant, Baricitinib, and Taltz. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. It maintains special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. It manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in about 120 countries.

  • Revenue in USD (TTM)29.07bn
  • Net income in USD5.69bn
  • Incorporated1901
  • Employees35.00k
  • Location
    Eli Lilly and CoLilly Corporate CtrDrop Code 1094, Lilly Corporate CtrINDIANAPOLIS 46285-0001United StatesUSA
  • Phone+1 (317) 276-2000
  • Fax+1 (317) 276-3492
  • Websitehttps://www.lilly.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Bristol-Myers Squibb Co47.14bn6.62bn149.79bn32.20k23.314.598.753.183.013.0121.4915.270.44654.586.001,464,
Merck & Co., Inc.57.17bn16.64bn218.32bn68.00k13.145.0510.753.826.566.5322.5317.070.57813.036.54840,720.6016.847.6121.8310.1470.7770.9229.1316.061.1521.890.422386.0617.314.12173.1825.7922.487.49
Pfizer Inc.101.13bn29.75bn245.99bn79.00k8.452.817.072.435.195.1117.6215.590.55383.947.861,280,152.0016.306.6221.148.2562.2174.0429.4421.321.2022.140.315375.7295.169.00238.0525.516.285.39
AbbVie Inc57.35bn12.57bn249.67bn50.00k19.9717.0411.944.357.077.0732.278.290.39394.955.421,146,980.008.697.4611.109.4670.7272.0322.0518.110.74568.270.832497.8922.6916.99151.7114.1310.4417.93
Eli Lilly And Co29.07bn5.69bn292.18bn35.00k49.0734.1940.0010.056.276.2732.028.990.61281.814.77830,591.4012.0011.0817.8315.8075.9877.1619.5820.770.8467.330.660153.7515.405.94-9.8815.3111.4010.76
Johnson & Johnson95.59bn18.37bn435.66bn141.70k24.095.7117.064.566.886.8835.8029.040.53982.856.16674,580.1010.379.9513.5712.7367.8966.8719.2119.211.17123.700.299262.3313.555.4644.854.772.515.87
Data as of Sep 29 2022. Currency figures normalised to Eli Lilly and Co's reporting currency: US Dollar USD

Institutional shareholders

35.99%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 202268.29m7.19%
PNC Bank, NA (Investment Management)as of 30 Jun 202252.08m5.48%
BlackRock Fund Advisorsas of 30 Jun 202240.19m4.23%
SSgA Funds Management, Inc.as of 30 Jun 202233.41m3.52%
Fidelity Management & Research Co. LLCas of 30 Jun 202229.57m3.11%
Capital Research & Management Co. (World Investors)as of 30 Jun 202228.74m3.03%
PRIMECAP Management Co.as of 30 Jun 202228.44m2.99%
Wellington Management Co. LLPas of 30 Jun 202223.44m2.47%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 202220.43m2.15%
State Farm Investment Management Corp.as of 30 Jun 202217.41m1.83%
More ▼
Data from 30 Jun 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.